Advanced endometrial cancer—The next generation of treatment: A society of gynecologic oncology journal club clinical commentary

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY Gynecologic Oncology Reports Pub Date : 2024-07-18 DOI:10.1016/j.gore.2024.101462

Todd Tillmanns , Amal Masri , Chelsea Stewart , Dana Chase , Anthony Karnezis , Lee-may Chen , Renata Urban

{"title":"Advanced endometrial cancer—The next generation of treatment: A society of gynecologic oncology journal club clinical commentary","authors":"Todd Tillmanns , Amal Masri , Chelsea Stewart , Dana Chase , Anthony Karnezis , Lee-may Chen , Renata Urban","doi":"10.1016/j.gore.2024.101462","DOIUrl":null,"url":null,"abstract":"<div><p>In February of 2024, the Society of Gynecologic Oncology (SGO) hosted a journal club focused on new treatment options for the management of advanced and metastatic endometrial cancer. This clinical commentary is intended to provide a summary report of that presentation. The session described the importance of molecular characterization shown in the work of The Cancer Genome Atlas (TCGA). The updated 2023 FIGO staging of endometrial cancer was reviewed. The panel then described the role of upfront immunotherapy for the treatment of advanced or recurrent endometrial cancer as demonstrated in four recent trials (RUBY, NRG-GY018, AtTEnd, and DUO-E studies). The DUO-E study uniquely examined the combination immunotherapy with a PARP inhibitor. The trials had unique differences in inclusion criteria, primary outcomes, and length of maintenance therapy, but all boasted similarly promising results particularly in mismatch repair deficient (dMMR) endometrial cancer. This era of rapid innovation in advanced and recurrent endometrial cancer will hopefully enhance individualized treatment approaches and improved outcomes for patients with endometrial cancer.</p></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352578924001413/pdfft?md5=07de959263f1b1783d0624cbe85715a9&pid=1-s2.0-S2352578924001413-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578924001413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In February of 2024, the Society of Gynecologic Oncology (SGO) hosted a journal club focused on new treatment options for the management of advanced and metastatic endometrial cancer. This clinical commentary is intended to provide a summary report of that presentation. The session described the importance of molecular characterization shown in the work of The Cancer Genome Atlas (TCGA). The updated 2023 FIGO staging of endometrial cancer was reviewed. The panel then described the role of upfront immunotherapy for the treatment of advanced or recurrent endometrial cancer as demonstrated in four recent trials (RUBY, NRG-GY018, AtTEnd, and DUO-E studies). The DUO-E study uniquely examined the combination immunotherapy with a PARP inhibitor. The trials had unique differences in inclusion criteria, primary outcomes, and length of maintenance therapy, but all boasted similarly promising results particularly in mismatch repair deficient (dMMR) endometrial cancer. This era of rapid innovation in advanced and recurrent endometrial cancer will hopefully enhance individualized treatment approaches and improved outcomes for patients with endometrial cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

晚期子宫内膜癌--新一代治疗方法：妇科肿瘤学会期刊俱乐部临床评论

2024 年 2 月，妇科肿瘤学会（SGO）举办了一次期刊俱乐部会议，重点讨论晚期和转移性子宫内膜癌的新治疗方案。本临床评论旨在提供该演讲的总结报告。会议介绍了癌症基因组图谱（TCGA）工作中显示的分子特征描述的重要性。会议回顾了最新的 2023 年 FIGO 子宫内膜癌分期。随后，专家小组介绍了近期四项试验（RUBY、NRG-GY018、AtTEnd 和 DUO-E 研究）所证明的前期免疫疗法在治疗晚期或复发性子宫内膜癌中的作用。DUO-E 研究对免疫疗法与 PARP 抑制剂的联合应用进行了独特的研究。这些试验在纳入标准、主要结果和维持治疗时间等方面都有独特的差异，但都取得了类似的令人鼓舞的结果，尤其是在错配修复缺陷（dMMR）子宫内膜癌方面。在晚期和复发性子宫内膜癌领域快速创新的时代，有望加强个体化治疗方法，改善子宫内膜癌患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.